VIR Vir Biotechnology
- 8.460
- +0.090+1.08%
- 8.440
- -0.020-0.24%
Vir Biotechnology News
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024
With 53% Ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) Boasts of Strong Institutional Backing
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology Announces CFO Departure and Board Expansion
Vir Biotechnology Announces Nomination of Norbert Bischofbergerm, Ramy Farid to Its Board of Directors
Vir Biotechnology Announces Nomination of Norbert Bischofbergerm, Ramy Farid to Its Board of Directors
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution
In the last year, many Vir Biotechnology, Inc. (NASDAQ:VIR) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it i
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Form 144 | Vir Biotechnology(VIR.US) Officer Proposes to Sell 350.58K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 4, $Vir Biotechnology(VIR.US)$ Officer Pang Phillip intends to sell 37,535 shares of its common stock on Apr 4, with a total market value of approximately $350.58K. Pang
Form 144 | Vir Biotechnology(VIR.US) Insider Proposes to Sell 504.59K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $Vir Biotechnology(VIR.US)$ Insider PHILLIP PANG intends to sell 53,000 shares of its common stock on Apr 3, with a total market value of approximately $504.59K. PHILL
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology with a Buy and maintains $110 price target.
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule
Vir Biotechnology (VIR) said Tuesday it completed enrollment of its current groups in a phase 2 clinical trial of tobevibart and elebsiran to treat chronic hepatitis delta virus one month earlier than
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
Optimistic Outlook for Vir Biotechnology's Clinical Programs and Financial Position Reinforces Buy Rating
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Is Maintained at Neutral by JP Morgan
Vir Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/23/2024 -13.16% JP Morgan $9 → $10 Maintains Neutral 02/14/2024 855.28% HC Wainwright & Co. $85 → $110
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Carvana Co. (NYSE:CVNA) rose sharply during Friday's session after the company reported four
Vir Biotechnology Shares Rise 14% on Terminated Collaboration With GSK
By Denny Jacob Vir Biotechnology shares rose 14% to $11.72 following a terminated collaboration with GSK regarding the flu. The stock is down about 55% over the last 12 months. The clinical-stage i
Analysis
Price Target
No Data
